Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints
By Colin Kellaher
A Phase 3 study of a cancer-drug combination from Merck & Co., Seagen and Astellas Pharma has met its key goals in certain patents with he most common type of bladder cancer.
The companies on Friday said the study that combined Merck's blockbuster cancer drug Keytruda with Astellas' and Seagen's Padcev versus chemotherapy met its dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
The companies said the combination also showed a statistically significant improvement in overall response rate, a key secondary endpoint of the study, which enrolled patients who may or may not be eligible for treatment with cisplatin-based chemotherapy, regardless of PD-L1 status.
Locally advanced or metastatic urothelial carcinoma is a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body.
Merck, Seagen and Astellas said the study is intended to serve as the basis for global submissions of the Keytruda/Padcev combination and as the confirmatory trial for the accelerated approval the U.S. Food and Drug Administration granted to the combination in April.
The companies, which formed a collaboration in late 2019 to study Padcev in combination with Keytruda in urothelial cancer, said they are evaluating the pairing as part of an extensive clinical development program in multiple stages of the disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 22, 2023 06:47 ET (10:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track